Catalina Capital Group LLC Grows Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Catalina Capital Group LLC raised its position in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 1.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,325 shares of the company’s stock after buying an additional 43 shares during the period. Eli Lilly and Company comprises about 1.1% of Catalina Capital Group LLC’s holdings, making the stock its 18th largest holding. Catalina Capital Group LLC’s holdings in Eli Lilly and Company were worth $3,339,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Chicago Capital LLC boosted its position in shares of Eli Lilly and Company by 43.7% during the fourth quarter. Chicago Capital LLC now owns 38,522 shares of the company’s stock worth $29,739,000 after buying an additional 11,709 shares during the period. Means Investment CO. Inc. boosted its holdings in Eli Lilly and Company by 6.8% in the fourth quarter. Means Investment CO. Inc. now owns 3,221 shares of the company’s stock valued at $2,487,000 after purchasing an additional 205 shares during the period. Abner Herrman & Brock LLC boosted its holdings in Eli Lilly and Company by 1.3% in the fourth quarter. Abner Herrman & Brock LLC now owns 26,857 shares of the company’s stock valued at $20,734,000 after purchasing an additional 349 shares during the period. Family Investment Center Inc. boosted its holdings in Eli Lilly and Company by 6.1% in the fourth quarter. Family Investment Center Inc. now owns 400 shares of the company’s stock valued at $309,000 after purchasing an additional 23 shares during the period. Finally, Magnolia Capital Advisors LLC boosted its holdings in Eli Lilly and Company by 27.0% in the fourth quarter. Magnolia Capital Advisors LLC now owns 583 shares of the company’s stock valued at $450,000 after purchasing an additional 124 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on LLY. Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a report on Monday, November 4th. Truist Financial lifted their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Wells Fargo & Company decreased their price target on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Finally, Bank of America reaffirmed a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $997.50.

Read Our Latest Report on Eli Lilly and Company

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Up 2.1 %

LLY opened at $827.41 on Wednesday. The business has a 50 day moving average price of $784.69 and a two-hundred day moving average price of $843.49. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a market cap of $785.48 billion, a PE ratio of 89.45, a P/E/G ratio of 1.72 and a beta of 0.42. Eli Lilly and Company has a 52 week low of $682.53 and a 52 week high of $972.53.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.73%. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Eli Lilly and Company declared that its Board of Directors has initiated a share repurchase program on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its stock is undervalued.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Articles

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.